-
-
-
-
-
-
-
AnaptysBio (ANAB) PT Lowered to $60 at UBS Following Spinoff of Biopharma Business
-
-
-
-
-
-
-
AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright
-
-
-
-
-
-
-
UBS Assumes AnaptysBio (ANAB) at Buy
-
-
-
-
-
-
-
Anaptysbio (ANAB) Halted, News Pending
-
-
-
-
-
-
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
-
-
-
-
-
-
AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 18c
-
-
-
-
-
-
-
Wolfe Research: 'Bullish long-term on ANAB'
-
456,295 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

